A combination of the personalized cancer vaccine intismeran autogene and Merck's Keytruda just barely cleared analysts’ ...
AbbVie is eyeing regulatory filings in 2027 for the skin disease drug lutikizumab after clearing multiple endpoints in a late ...
Eli Lilly and Company (NYSE: LLY) broke ground today on a new $5 billion manufacturing facility just west of Richmond, ...
U.S. Patent No. 12,734,179 B2, titled Progesterone formulation to trigger ovulation and provide luteal phase support, was ...
After cardiac safety signals led to a full clinical hold on Aardvark Therapeutics’ studies of ARD-101, the biotech conducted ...
Completion of light dose-escalation Part A of Phase 1 study identifies regimen for further evaluation in Part B, supporting ...
MESA, AZ / ACCESS Newswire / October 23, 2026 / Medical Care Technologies Inc. (OTCID:MDCE) today announced that it is ...
Labcorp intends to be the first commercial laboratory to offer FDA-approved HPV testing with the BD Onclarity™ HPV Assay ...
(Biokin) reported positive results from a prespecified interim analysis of the randomized Phase 3 PANKU-Breast01 study ...
CorWave SA, a clinical-stage medical technology company pioneering innovative cardiac assist devices, announces the ...
Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, today ...
Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026
Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results